Sign In
Buy IONS
$55.07
+0.580 (+1.06%)
At Close: Aug 04, 2026
Ionis to hold first quarter 2023 financial results webcast
07:05am, Thursday, 20'th Apr 2023
Webcast scheduled for Wednesday, May 3 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
Could This Rare-Disease Drug Candidate Become a Blockbuster?
09:15am, Wednesday, 19'th Apr 2023
AstraZeneca and Ionis recently shared promising phase 3 clinical trials for eplontersen. If approved, the drug candidate could top $1 billion in annual sales -- split between the two companies.
Ionis to present at upcoming investor conferences
07:05am, Tuesday, 28'th Mar 2023
CARLSBAD, Calif. , March 28, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced its participation in fireside chats at the following investor conferences: Guggenheim Virtu
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
12:59pm, Monday, 27'th Mar 2023
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Why Is Ionis Pharmaceuticals (IONS) Down 8.4% Since Last Earnings Report?
12:59pm, Friday, 24'th Mar 2023
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
09:25am, Thursday, 23'rd Mar 2023
Ionis stock jumped Thursday after an FDA panel offered a mixed view of its Biogen-partnered drug for ALS. The post Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement appeared first on Inv
Wall Street predicts approval for another ALS drug
11:45am, Tuesday, 21'st Mar 2023
It appears likely that a new drug to treat amyotrophic lateral sclerosis (ALS) will get approval in the U.S. Regulators shared their thinking ahead of an advisory committee meeting.
Ionis to present at upcoming investor conferences
07:05am, Tuesday, 28'th Feb 2023
CARLSBAD, Calif. , Feb. 28, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the following investor conferences: Cowen 43rd Annual Health
Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down
10:32am, Thursday, 23'rd Feb 2023
Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates.
Ionis Pharmaceuticals, Inc. (IONS) Q4 2022 Earnings Call Transcript
02:57pm, Wednesday, 22'nd Feb 2023
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q4 2022 Results Conference Call February 22, 2023 11:30 AM ET Company Participants Wade Walke - SVP, IR Brett Monia - CEO Beth Hougen - CFO Eugene Schneider
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Misses Revenue Estimates
09:47am, Wednesday, 22'nd Feb 2023
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 65.09% and 3.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock
Earnings Preview: Ionis Pharmaceuticals (IONS) Q4 Earnings Expected to Decline
11:17am, Wednesday, 15'th Feb 2023
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis to hold fourth quarter and full year 2022 financial results webcast
07:05am, Wednesday, 08'th Feb 2023
Webcast scheduled for Wednesday, February 22 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
Royalty Pharma agrees to buy Ionis Pharma royalties for $1.125 bln
09:24am, Monday, 09'th Jan 2023
Royalty Pharma Plc RPRX, -1.42% said Monday it agreed to pay up to $1.125 billion for drug royalties owned by Ionis Pharmaceuticals Inc. IONS, +1.00% . The royalties include Ionis' interests in Biogen
Ionis to present at 41st Annual J.P. Morgan Healthcare conference
07:05am, Wednesday, 04'th Jan 2023
CARLSBAD, Calif. , Jan. 4, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P.
